Orthocell secures Remplir™ approval across U.S. Department of Defence Hospital Network
Orthocell has secured approval for Remplir™ to be used across the United States Department of Defence and Veterans Affairs (VA) hospital networks, marking a significant step forward in the Company’s U.S. commercial strategy.
The approval provides access to approximately 51 Department of Defence military hospitals and 170 Veterans Affairs medical centres across the United States. Together, these hospital networks represent an important expansion opportunity for Remplir in a key healthcare segment.
Orthocell will now leverage its established U.S. distributor network to target military and VA surgeons operating within these hospital systems. The Company’s distributor footprint currently covers 17 states, with a significant portion of these facilities able to be serviced through existing distribution channels, supporting efficient market penetration.
The milestone adds to Orthocell’s growing progress in the U.S. market. The Company has already secured 32 Value Analysis Committee approvals, providing access to more than 115 hospitals, with a further 57 applications currently pending approval. This expanding access comes as Orthocell continues to see increasing commercialisation and revenue momentum in the United States.
The approval also follows recent clinical use of Remplir in 23 surgical procedures on injured soldiers in Ukraine across both primary and secondary nerve repair applications. That experience demonstrated the device’s real-world performance in a conflict environment and highlighted attributes including portability, ease of use, and suitability for treating major traumatic injuries commonly encountered in military settings.
Orthocell believes this validation further supports Remplir’s applicability within defence healthcare systems and reinforces its potential to address the needs of military surgeons treating complex nerve injuries.
Paul Anderson, Orthocell Managing Director, said securing access to the U.S. Department of Defence and Veterans Affairs hospital networks represents a major milestone for the Company and an important advance in its U.S. commercial expansion.
“This approval enables us to engage directly with military and VA surgeons treating complex nerve injuries and to leverage our existing distributor network to drive adoption of Remplir across these key institutions.
“Importantly, Remplir has already demonstrated its value in conflict-related injuries in Ukraine, highlighting its suitability for the types of traumas commonly encountered within military healthcare systems.
“Orthocell is well positioned to capitalise on this expanded access with its existing network of distributors and in-house sales and medical education teams and will continue to pursue opportunities to increase utilisation of Remplir across key U.S. healthcare segments, including military and veteran care.”
Click to read the ASX release.